WiSE CRT Is Beneficial for Heart Failure Patients as a Rescue Therapy: Evidence From a Meta-Analysis.
CRT
WiSE system
endocardial pacing
heart failure
leadless cardiac pacing
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
11
2021
accepted:
08
02
2022
entrez:
4
4
2022
pubmed:
5
4
2022
medline:
5
4
2022
Statut:
epublish
Résumé
Leadless endocardial left ventricular (LV) pacing resynchronization therapy is a novel solution for patients with heart failure (HF) in whom conventional cardiac resynchronization therapy (CRT) failed. PubMed and the Cochrane Library were searched for relevant cohort studies. Clinical outcomes of interest such as ejection fraction (EF), QRS duration (QRSd), and left ventricular end-systolic volume (LVESV) were extracted and analyzed. Five studies involving 175 HF patients for WiSE CRT were included, and patients were followed-up for 6 months. The implanted success rate ranged from 76.5 to 100%. WiSE CRT resulted in significantly narrower QRSd [mean difference (MD): -38.21 ms, 95% confidence interval (CI): -44.36 to -32.07, Evidence from current studies suggests that leadless endocardial LV pacing resynchronization is effective for HF patients who failed conventional CRT or needed a device upgrade, and it may be an interesting rescue therapy.
Sections du résumé
Background
UNASSIGNED
Leadless endocardial left ventricular (LV) pacing resynchronization therapy is a novel solution for patients with heart failure (HF) in whom conventional cardiac resynchronization therapy (CRT) failed.
Methods
UNASSIGNED
PubMed and the Cochrane Library were searched for relevant cohort studies. Clinical outcomes of interest such as ejection fraction (EF), QRS duration (QRSd), and left ventricular end-systolic volume (LVESV) were extracted and analyzed.
Results
UNASSIGNED
Five studies involving 175 HF patients for WiSE CRT were included, and patients were followed-up for 6 months. The implanted success rate ranged from 76.5 to 100%. WiSE CRT resulted in significantly narrower QRSd [mean difference (MD): -38.21 ms, 95% confidence interval (CI): -44.36 to -32.07,
Conclusion
UNASSIGNED
Evidence from current studies suggests that leadless endocardial LV pacing resynchronization is effective for HF patients who failed conventional CRT or needed a device upgrade, and it may be an interesting rescue therapy.
Identifiants
pubmed: 35369306
doi: 10.3389/fcvm.2022.823797
pmc: PMC8964787
doi:
Types de publication
Systematic Review
Langues
eng
Pagination
823797Informations de copyright
Copyright © 2022 Cang, Liu, Zhu, Liu, Shen, Miao, Zhou and Chen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Europace. 2020 Feb 1;22(2):298
pubmed: 31504436
J Am Coll Cardiol. 2017 May 2;69(17):2119-2129
pubmed: 28449772
Heart Rhythm. 2020 Aug;17(8):1291-1297
pubmed: 32165181
JAMA. 2007 Jun 13;297(22):2502-14
pubmed: 17565085
Am Heart J. 2019 Nov;217:13-22
pubmed: 31472360
Can J Cardiol. 2017 Dec;33(12):1736.e1-1736.e3
pubmed: 29173611
Heart Rhythm. 2022 Jan;19(1):22-29
pubmed: 34332966
J Am Coll Cardiol. 2007 Aug 28;50(9):877-83
pubmed: 17719475
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Europace. 2014 May;16(5):681-8
pubmed: 24497573
Europace. 2021 May 21;23(5):740-747
pubmed: 33313789
Herzschrittmacherther Elektrophysiol. 2018 Dec;29(4):340-348
pubmed: 30406825
Europace. 2010 Jul;12(7):961-7
pubmed: 20444725
Europace. 2021 Oct 9;23(10):1577-1585
pubmed: 34322707
Circulation. 2000 Feb 29;101(8):869-77
pubmed: 10694526
Europace. 2013 Aug;15(8):1191-7
pubmed: 23703364
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Eur Heart J. 2007 May;28(10):1182-3
pubmed: 17459903
Eur J Heart Fail. 2013 Dec;15(12):1419-28
pubmed: 24259043
Heart Rhythm. 2006 Oct;3(10):1202-6
pubmed: 17018352
Expert Rev Med Devices. 2018 Aug;15(8):555-570
pubmed: 30019954